Drug Trial Radar · NCT03157635
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Nov 14, 2016
Primary completion
Aug 13, 2026
Study completion Aug 13, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- May 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of crovalimab will be evaluated in participants with paroxysmal nocturnal hemoglobinuria (PNH) in parts 2, 3, 4, and OLE of the study. Efficacy of crovalimab will be evaluated in Parts 2, 3, and 4.
Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
Interventions
CrovalimabDrug
Crovalimab will be administered as per schedule described in individual arm.
PlaceboDrug
Placebo will be administered as per schedule described in Part 1 placebo arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percentage of Participants With Dose-Limiting Events (DLEs)Time frame: Baseline up to approximately 3 months
- Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to approximately 3 months
- Part 2: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
- Part 3: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
- Part 4: Percentage of Participants With AEs and SAEsTime frame: Baseline up to approximately 8 months
- Part 2: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)Time frame: Baseline up to Day 224
- Part 3: Terminal Complement Activity as Assessed by Ex Vivo Liposome Lysis in Serum Using the LIATime frame: Baseline up to Day 224
- Part 4: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA)Time frame: Baseline up to Day 224
- OLE: Percentage of Participants With AEs and SAEsTime frame: OLE: Week 21 up to Week 567
Locations
15 sites in 7 countries. Site status is shown where the registry gives one.
Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis
Paris, France
Uniklinik RWTH Aachen
Aachen, Germany
Universitätsklinikum Essen
Essen, Germany
Universitätsklinikum Ulm
Ulm, Germany
Semmelweis Egyetem, 1. Szamu Belgyogyaszati Klinika, Diabetologia
Budapest, Hungary
Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology
Kaposvár, Hungary
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
Tohoku University Hospital
Miyagi, Japan
Osaka University Hospital
Osaka, Japan
NTT Medical Center Tokyo
Tokyo, Japan
Tokyo Medical University Hospital
Tokyo, Japan
University of Tsukuba Hospital
Tsukuba, Japan
Pra International Group B.V
Groningen, Netherlands
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Seoul National University Hosp
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.